Chiusura precedente | 1,7000 |
Aperto | 0,0000 |
Denaro | 0,0000 x N/D |
Lettera | 0,0000 x N/D |
Min-Max giorno | 0,0000 - 0,0000 |
Intervallo di 52 settimane | |
Volume | |
Media Volume | 90 |
Capitalizzazione | 427.293 |
Beta (5 anni mensile) | 0,94 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,4060 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology. Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costim
Planegg/Martinsried, September 11, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the Baader Investment Conference 2023 in Munich to be held from September 18-21, 2023. Corporate presentation - Baader Investment Conference 2023 https://www.baaderinvestmentconference.com/Date and time: Monday, September 18, 2023, 2:10 pm – 2:50